Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 60,432 call options on the stock. This is an increase of approximately 148% compared to the average daily volume of 24,409 call options.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RXRX. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $27,000. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $36,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC lifted its position in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Up 20.1%

NASDAQ RXRX traded up $0.92 on Friday, hitting $5.49. The stock had a trading volume of 59,957,988 shares, compared to its average volume of 14,331,794. The business's fifty day moving average price is $4.81 and its 200 day moving average price is $6.35. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of -3.59 and a beta of 0.84. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a 52-week low of $3.79 and a 52-week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same quarter last year, the firm earned ($0.39) earnings per share. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts anticipate that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on RXRX. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Morgan Stanley cut their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average price target of $7.60.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.